The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial

被引：0
|
作者：
M Gnant
G Pfeiler
H Stöger
B Mlineritsch
F Fitzal
M Balic
W Kwasny
M Seifert
M Stierer
P Dubsky
R Greil
G Steger
H Samonigg
C Fesl
R Jakesz
机构：
[1] Comprehensive Cancer Center,Department of Surgery
[2] Medical University of Vienna,Division of Gynecology and Gynecological Oncology, Department of OB/GYN
[3] Comprehensive Cancer Center,Department of Medical Oncology
[4] Medical University of Vienna,IIIrd Medical Department with Hematology and Medical Oncology
[5] Medical University of Graz,Department of Surgery
[6] Hemostaeology,Department of Surgery
[7] Infectious Disease and Rheumatology,Division of Oncology, Department of Internal Medicine I
[8] Oncology Center,Department of Statistics
[9] Paracelus Medical University Hospital Salzburg,undefined
[10] Wiener Neustadt Hospital,undefined
[11] Hanusch Medical Center,undefined
[12] Medical University of Vienna,undefined
[13] Austrian Breast and Colorectal Cancer Study Group,undefined
来源：
British Journal of Cancer | 2013年 / 109卷
关键词：
breast cancer; endocrine therapy; BMI; aromatase inhibitor; extended therapy; obesity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：589 / 596
页数：7
相关论文
共 50 条
  • [31] Impact of body mass index on the efficacy of endocrine therapy in patients with metastatic breast cancer - A retrospective two-center cohort study
    Zewenghiel, Luwam
    Lindman, Henrik
    Valachis, Antonis
    [J]. BREAST, 2018, 40 : 136 - 140
  • [32] Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial
    Del Mastro, Lucia
    Mansutti, Mauro
    Bisagni, Giancarlo
    Ponzone, Riccardo
    Durando, Antonio
    Amaducci, Laura
    Campadelli, Enrico
    Cognetti, Francesco
    Frassoldati, Antonio
    Michelotti, Andrea
    Mura, Silvia
    Urracci, Ylenia
    Sanna, Giovanni
    Gori, Stefania
    De Placido, Sabino
    Garrone, Ornella
    Fabi, Alessandra
    Barone, Carla
    Tamberi, Stefano
    Bighin, Claudia
    Puglisi, Fabio
    Moretti, Gabriella
    Arpino, Grazia
    Ballestrero, Alberto
    Poggio, Francesca
    Lambertini, Matteo
    Montemurro, Filippo
    Bruzzi, Paolo
    [J]. LANCET ONCOLOGY, 2021, 22 (10): : 1458 - 1467
  • [33] Health economic impact of breast cancer index (BCI) in patients with hormone responsive breast cancer (HRBC) considering extended adjuvant endocrine therapy (EET).
    Sanft, Tara Beth
    Berkowitz, Alyssa
    Schroeder, Brock
    Hatzis, Christos
    Schnabel, Catherine A.
    Aktas, Bilge
    Brufsky, Adam M.
    Pusztai, Lajos
    Gustavsen, Gary
    Van Londen, G. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (08)
  • [34] Body mass index as a predictive factor for efficacy of taxane-based chemotherapy in early breast cancer patients
    Garcia-Saenz, J. A.
    Spera, G.
    Pollan, M. A.
    Bermejo, B.
    Ruiz Borrego, M.
    Chan, A.
    Martin Jimenez, M.
    Guerrero Zotano, A. L.
    Calvo-Martinez, L.
    Rodriguez-Lescure, A.
    Arcusa Lanza, A.
    Chap, L. I.
    Crown, J. P.
    Bee-Munteanu, V.
    Casas, M.
    Polonio, O.
    Slamon, D.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S283 - S284
  • [35] Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial
    Bartlett, J. M. S.
    Sgroi, D. C.
    Treuner, K.
    Zhang, Y.
    Ahmed, I
    Piper, T.
    Salunga, R.
    Brachtel, E. F.
    Pirrie, S. J.
    Schnabel, C. A.
    Rea, D. W.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (11) : 1776 - 1783
  • [36] Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial.
    Gnant, Michael
    Pfeiler, Georg
    Steger, Guenther G.
    Egle, Daniel
    Greil, Richard
    Fitzal, Florian
    Wette, Viktor
    Balic, Marija
    Haslbauer, Ferdinand
    Melbinger-Zeinitzer, Elisabeth
    Bjelic-Radisic, Vesna
    Bergh, Jonas C. S.
    Jakesz, Raimund
    Marth, Christian
    Sevelda, Paul
    Mlineritsch, Brigitte
    Exner, Ruth
    Fesl, Christian
    Frantal, Sophie
    Singer, Christian F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [37] EFFICACY OF FULVESTRANT ACCORDING TO DURATION AND TYPE OF ADJUVANT ENDOCRINE TREATMENT, IN METASTATIC BREAST CANCER PATIENTS ENROLLED IN THE CONFIRM TRIAL
    Malorni, L.
    Biagioni, C.
    Thirlwell, J.
    Guarducci, C.
    Bonechi, M.
    Rukazenkov, Y.
    Jerusalem, G.
    Martin, M.
    di Leo, A.
    Migliaccio, I.
    [J]. ANNALS OF ONCOLOGY, 2014, 25 : 11 - 11
  • [38] 10 years or less of extended adjuvant endocrine therapy for postmenopausal breast cancer patients: A systematic review and network meta-analysis
    Petrelli, Fausto
    Cavallone, Matteo
    Dottorini, Lorenzo
    [J]. EUROPEAN JOURNAL OF CANCER, 2023, 193
  • [39] Effect of body mass index on the efficacy of adjuvant tamoxifen in premenopausal patients with hormone receptor-positive breast cancer
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Ozdemir, Nuriye Y.
    Zengin, Nurullah
    Yazici, Ozan
    Sever, Ali R.
    Altundag, Kadri
    [J]. JOURNAL OF BUON, 2016, 21 (01): : 27 - 34
  • [40] Efficacy of adjuvant tamoxifen in hormone receptor-positive premenopausal breast cancer patients according to the body mass index
    Altundag, Kadri
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Babacan, Taner
    Ozisik, Yavuz
    [J]. CANCER RESEARCH, 2015, 75
12345